Abstract
Despite the recognized role of Epstein-Barr virus (EBV) in predisposing to multiple sclerosis (MS) and the effectiveness of B cell-depleting therapies in MS, the mechanism of autoimmunity remains elusive. Using fine needle aspirations, we investigated deep cervical lymph nodes (dcLNs), the primary site of the adaptive immune response against EBV, in newly diagnosed untreated MS patients and healthy controls. We characterized the immune landscape of dcLNs with scRNAseq and CITE- seq and observed increased memory B cell proportions and reduced germinal center (GC) B cells with decreased clonality in patients with MS compared to healthy controls. In the patient with an active MS relapse, we detected elevated plasmablasts, reduced GC B cells, and clonally expanded memory CD8 T cells targeting EBV in the dcLN. These findings, along with increased EBV DNA detection in dcLNs and viral loads in patient saliva, support B cell dysregulation as a key mechanism in MS pathogenesis.
Competing Interest Statement
SML: lecture fees Argenx, Biogen, Janssen, Merck, Novartis, Roche; congress expenses Merck, Novartis; advisory fee Argenx, Novartis, Roche, Sanofi, UCB Pharma; investigator for the clinical study Clarion (Merck) and sub-investigator for the clinical study Fenhance (Roche) PJT: Congress expenses Biogen, Novartis, Merck KGaA, Teva; fees for lectures Biogen, Roche, Novartis, Sanofi-Genzyme, Merck, Teva, Orion, Santen, Alexion.
Funding Statement
Academy of Finland grant 332186 (SML) Competitive Research Funding of the State of Finland governed through Helsinki University Hospital grant TYH2020317 (SML) Finska Lakaresallskapet (SML) Suomen MS-Saatio (JS) Emil Aaltonen Foundation (JS) Instrumentarium Science Foundation (JS) Suomen Laaketieteen saatio grant 6006 (MP) Liv och Halsa (MP)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Helsinki University Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The Seurat-objects of the processed scRNA-sequencing data including TCR and BCR and CITE-seq data are available at Zenodo (10.5281/zenodo.10006020) with restricted access due to GDPR regulations and data can be accessed by placing a request via Zenodo. Differentially expressed gene sets are available in supplementary data files. The reconstructed near-complete HHV-7 genomes are available at GenBank (OR634979 and OR634980).
